| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | C BAS/HAS antibody; C HA RAS1 antibody; C-BAS/HAS antibody; c-H-ras antibody; C-HA-RAS1 antibody; CTLO antibody; GTPase HRas antibody; GTPase KRas antibody; GTPase NRas antibody; H ras antibody; H RASIDX antibody; H-Ras-1 antibody; H-RASIDX antibody; Ha-Ras antibody; HAMSV antibody; HRAS antibody; HRAS1 antibody; K ras antibody; K RAS2A antibody; K RAS2B antibody; K RAS4A antibody; K RAS4B antibody; K-RAS antibody; KRAS antibody; KRAS1 antibody; KRAS2 antibody; N-RAS antibody; N-terminally processed antibody; NRAS antibody; NRAS1 antibody; p21ras antibody; RASH_HUMAN antibody; RASH1 antibody; RASK2 antibody; Transforming protein p21 antibody; v Ha ras Harvey rat sarcoma viral oncogene homolog antibody; v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody; v ras neuroblastoma RAS viral oncogene homolog antibody |
| Clonality | |
| Conjugate | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide from human HRAS protein |
| Isotype | |
| Product Type | |
| Reactivity | |
| Source | This product is a recombinant monoclonal antibody expressed in HEK293F cells. |
| Storage | |
| Target | |
| UniProt # |
Overview
This is a monoclonal anti-HRAS antibody raised in Rabbit, with confirmed utility in ELISA, IHC, IF, FC. It is designed to detect HRAS protein in Human and supports researchers working in others contexts.
Key elements and design rationale
- Immunogen: A synthesized peptide from human HRAS protein — determines the epitope region; confirm compatibility with sample preparation and expected post-translational modifications.
- Host species (Rabbit): Requires anti-rabbit-IgG secondary reagents for indirect detection.
- Monoclonal format: Single-epitope binding provides high specificity and lot-to-lot reproducibility. Confirm epitope accessibility under your assay conditions.
- Isotype (IgG): Matched secondary antibodies and isotype controls required. Compatible with standard Protein A/G purification workflows.
- Purification (Affinity chromatography): Enriches for specific immunoglobulin classes; reduces non-specific background vs. crude antisera.
Biological background
HRAS (also referred to as C BAS/HAS antibody, C HA RAS1 antibody, C-BAS/HAS antibody, c-H-ras antibody, C-HA-RAS1 antibody, CTLO antibody, GTPase HRas antibody, GTPase KRas antibody, GTPase NRas antibody, H ras antibody, H RASIDX antibody, H-Ras-1 antibody, H-RASIDX antibody, Ha-Ras antibody, HAMSV antibody, HRAS antibody, HRAS1 antibody, K ras antibody, K RAS2A antibody, K RAS2B antibody, K RAS4A antibody, K RAS4B antibody, K-RAS antibody, KRAS antibody, KRAS1 antibody, KRAS2 antibody, N-RAS antibody, N-terminally processed antibody, NRAS antibody, NRAS1 antibody, p21ras antibody, RASH_HUMAN antibody, RASH1 antibody, RASK2 antibody, Transforming protein p21 antibody, v Ha ras Harvey rat sarcoma viral oncogene homolog antibody, v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody, v ras neuroblastoma RAS viral oncogene homolog antibody) is a protein target studied in Human systems. Expression, subcellular localization, and post-translational modifications vary across cell types and disease states — factors critical to antibody-based detection design. Consult UniProt, NCBI Gene, and primary literature for current annotation of HRAS biology in others.
Common research applications
- ELISA: Quantification of soluble target in biological fluids or culture supernatants. Ensure samples are within the linear detection range.
- IHC: Visualization of target in FFPE or frozen tissue sections. Optimize antigen retrieval and secondary detection for each tissue type.
- IF: Subcellular localization in fixed cells or tissue sections; fixation and permeabilization conditions affect epitope accessibility.
- FC: Applicable for FC-based detection; refer to product documentation for optimized conditions.
Notes for experimental interpretation
- Isotype controls: Use an isotype-matched (IgG from Rabbit) control at equivalent concentration to assess non-specific background.
- Cross-reactivity: Confirm the clone does not cross-react with related family members under your assay conditions.
- Matrix effects: Sample matrix can affect performance; pilot dilution linearity and spike-recovery experiments are advised for quantitative studies.
- Species reactivity: Confirmed for Human. Extrapolation to untested species requires empirical validation.
This product is a recombinant monoclonal antibody expressed in HEK293F cells.
HRAS is a protein target in Human biology. This monoclonal antibody raised in Rabbit is designed to detect HRAS in ELISA, IHC, IF, FC applications, with IgG isotype.
Reported reactive against Human. Immunogen derived from Human. Cross-reactivity with other species should not be assumed without documented data or empirical testing.
Reported for ELISA, IHC, IF, FC. Each format requires independent dilution optimization and appropriate controls. Unlisted applications require empirical testing.
This non-conjugated IgG antibody requires a compatible secondary. Select anti-rabbit IgG secondary conjugated to your preferred reporter (HRP, AP, fluorophore, or biotin), matched to IgG.
(1) Isotype control — IgG from Rabbit at matching concentration; (2) Positive control — known HRAS-expressing cell/tissue; (3) Negative control — knockdown/knockout sample for specificity; (4) Dilution linearity — verify proportional signal decrease in your matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
